XEIA Venture Partners

InvestorActive
Type: Venture FundStage: Pre-Seed, SeedSeries: Fund IILocation: CA, United StatesContinent: North AmericaWebsite

XEIA Venture Partners (X-disciplinary Exploration, Investment & Acceleration) is an early-stage venture capital firm founded in 2021 and headquartered in San Francisco, California. Formerly known as Empath Ventures, the firm invests in startups at the intersection of life sciences, AI, hardware, software, deep tech, and health tech under a thesis it calls 'Human 3' — a framework centered on advancing human health, wellbeing, and performance. Portfolio companies span neurotechnology (brain-computer interfaces, neuromodulation), drug discovery, psychedelic therapeutics, genetic medicine, and biosensors, with investments including TippingPoint Biosciences, Coherence, NeuroBionics, Motif, Synchron, and Mindstate Design Labs. The firm is led by Founding Partner Brom Rector (AI/ML) and Partner Sam Rector (medicinal chemistry, psychoactive pharmacology), with scientific advisory from Li-Huei Tsai, PhD, Director of MIT's Aging Brain Initiative. XEIA operates at least two funds: the original Empath Ventures Fund (now closed) and XEIA Venture Partners Fund II.

Deep Tech (Generalist)Biotech, Life Sciences, Synthetic BiologyAI and Machine LearningHealthcare and Med TechNeurotechnology

Founder Intel

Sign in to read intel from founders who have worked with XEIA Venture Partners.

What founders say about XEIA Venture Partners

Be the first to share intel on XEIA Venture Partners — it's free.

Get Started Free